In the MyPathway phase II basket trial, the efficacy of the two anti-HER2 agents, pertuzumab and trastuzumab, in patients with refractory metastatic HER2 positive CRC and HER2 status have been evaluated not only by IHC and FISH but also by NGS [109]. The gene discussed is ERBB2; the disease is colorectal carcinoma.